Pancreatic cancer is the fifth most common cause of cancer death in the UK. Around 10,500 people receive the diagnosis every year — and only 7% survive five years or more. The disease is particularly devastating because it so rarely produces clear symptoms in its early stages, and more than half of patients die within three months of diagnosis. Against this sobering backdrop, the question of whether pancreatic cancer shows in blood tests is one of the most clinically important questions in UK oncology. The honest, evidence-based answer is that no blood test currently available can definitively diagnose pancreatic cancer — but blood tests play a meaningful role in the diagnostic pathway, and a genuinely promising new development from a UK university may soon transform early detection entirely.
Understanding what current blood tests can and cannot tell you — and what to do if you have concerns — is the most important first step you can take.
Why Pancreatic Cancer Is So Difficult to Detect Early
The pancreas sits deep in the abdomen, tucked behind the stomach and surrounded by other organs. This anatomical position means that even a growing tumour can remain entirely invisible to the person carrying it for a considerable period. The symptoms it eventually produces — abdominal or back pain, jaundice, unexplained weight loss, changes in bowel habit, new-onset diabetes — are non-specific and can be caused by a wide range of far more common and benign conditions. By the time these symptoms prompt a GP visit, investigation, and diagnosis, the cancer has frequently already spread beyond the pancreas.
According to Cancer Research UK, there is currently no national screening programme for pancreatic cancer in the UK. Unlike bowel cancer, which has the FIT home testing kit, or cervical cancer, which has the smear test, there is no established blood-based or imaging tool that is sensitive, specific, and cost-effective enough to justify population-wide screening for pancreatic cancer. This is one of the most pressing unmet needs in UK cancer medicine — and it is the context in which the blood test developments described below matter so much.
Blood Tests Currently Used in Pancreatic Cancer Assessment
CA19-9: The Primary Tumour Marker
The most widely used blood marker in suspected and confirmed pancreatic cancer is CA19-9 — cancer antigen 19-9. As Pancreatic Cancer UK explains, CA19-9 is a protein that can be elevated in the presence of pancreatic cancer and is measured as part of the initial blood test assessment. According to Lab Tests Online UK and the Royal Surrey NHS Foundation Trust — whose guidance is aligned with NICE guideline NG85 — CA19-9 is the tumour marker most commonly associated with pancreatic cancer and is included in the blood tests requested when the disease is suspected.
However, the limitations of CA19-9 are significant and well-documented. As Pancreatic Cancer UK clearly states, not all pancreatic cancers produce tumour markers — and conditions that are not cancer can also produce them. CA19-9 can be elevated in pancreatitis, gallstones, jaundice, liver disease, ovarian cancer, and other gastrointestinal conditions. Crucially, around 10% of people do not produce CA19-9 at all due to their blood group genetics — meaning the test will always return a normal result in these individuals regardless of whether cancer is present. Lab Tests Online UK is equally direct: CA19-9 is not useful for detection or diagnosis in isolation because it is not elevated in all cases and is not specific to pancreatic cancer.
The greatest clinical value of CA19-9 is therefore not in initial diagnosis but in monitoring: if CA19-9 is raised at the point of diagnosis, it can subsequently be used to assess the effectiveness of treatment and to detect recurrence. A falling CA19-9 during chemotherapy suggests a response to treatment; a rising CA19-9 after a period of stability may indicate disease progression.
CEA — Carcinoembryonic Antigen
CEA is a second tumour marker that may be measured alongside CA19-9 in the assessment of suspected pancreatic cancer. Like CA19-9, CEA is not diagnostic in isolation — it can be raised in many other cancers and in non-cancerous conditions including smoking, liver disease, and inflammatory bowel conditions. According to Cancer Research UK, it may be used to help assess treatment response and monitor for recurrence if elevated at the time of diagnosis, rather than as a primary detection tool.
Liver Function Tests and Bilirubin
Jaundice — a yellowing of the skin and whites of the eyes caused by a build-up of bilirubin — is often one of the first noticeable signs of pancreatic cancer, particularly cancer affecting the head of the pancreas, which sits close to the bile duct. When a pancreatic tumour obstructs the bile duct, bilirubin cannot drain normally and accumulates in the blood. Liver function blood tests — which measure bilirubin alongside liver enzymes such as ALT and ALP — are therefore an important part of any assessment of suspected pancreatic cancer. According to both the American Cancer Society and Lab Tests Online UK, an elevated bilirubin strongly suggests bile duct obstruction, whether from a tumour, a gallstone, or another cause. A raised ALT may indicate that the tumour has spread to the liver.
Full Blood Count and Other Markers
A full blood count provides a baseline assessment of overall health and can flag anaemia, which may develop as a consequence of cancer. Amylase and lipase — enzymes produced by the pancreas — may be raised if a tumour obstructs the ducts through which pancreatic juice flows into the intestine, though elevated amylase is more commonly associated with pancreatitis than cancer. Blood calcium is sometimes elevated in pancreatic cancer, as in other cancers, producing symptoms including weakness, nausea, and abdominal pain. None of these markers is diagnostic, but taken together with clinical history and imaging, they contribute meaningfully to the overall clinical picture.
A patient seen at our Birmingham clinic — a man in his early sixties — presented with several weeks of upper abdominal discomfort, unexplained weight loss of around four kilograms, and a mildly yellow tinge to his eyes. A same-day private blood test revealed significantly elevated bilirubin and a raised CA19-9. He was referred urgently for CT imaging the same afternoon. The scan identified a mass at the head of the pancreas, and specialist referral was arranged within 48 hours. His early presentation — despite symptoms that could easily have been attributed to other causes — gave him access to a wider range of treatment options than he would have had at a later stage.
A Significant Breakthrough: The Four-Marker Blood Test
The most exciting recent development in pancreatic cancer blood testing — and one with direct relevance to UK patients — comes from research published in the respected journal Clinical Cancer Research in early 2026. A study led by researchers at Queen Mary University of London identified a combination of four blood biomarkers that, when measured together, achieved an overall accuracy of 91.9% in distinguishing pancreatic cancer patients from non-cancer cases. Importantly, the four-marker test identified early-stage pancreatic cancer in 87.5% of cases examined — a figure that represents a substantial improvement over CA19-9 alone.
The four markers combine CA19-9 and thrombospondin 2 (THBS2) — both previously studied but insufficient as standalone tools — with two additional novel biomarkers. The test proved particularly effective at differentiating pancreatic cancer patients from both healthy individuals and those with non-cancerous pancreatic conditions such as pancreatitis, which has historically been one of the most challenging diagnostic distinctions to make.
Professor Tatjana Crnogorac-Jurcevic, a pancreatic cancer expert at Queen Mary University of London, described the research as well-executed and noted it represents one of many efforts to develop a much-needed test for early detection of pancreatic cancer. She highlighted that the test performs particularly well at stages one and two — the stages at which surgical intervention remains possible — and that it offers genuine promise for the future of pancreatic cancer diagnosis.
It is important to be clear about where this test currently stands in the UK. The blood samples used in the study were collected retrospectively — meaning the cancer diagnosis was already known when the samples were analysed. Professor Crnogorac-Jurcevic noted that the biomarkers require further extensive validation in prospective studies before the test could enter routine clinical practice. Clinical implementation remains some years away. But the accuracy achieved is genuinely remarkable by the standards of existing pancreatic cancer diagnostics — and UK researchers are at the forefront of this work.
There Is Currently No Screening Blood Test for the General Population
This point deserves clear and honest emphasis. According to Cancer Research UK, there is no established blood test that can be used to screen the general population for pancreatic cancer. The complexity of the disease, the variability of markers between patients, and the high rate of false positives from conditions that are not cancer have prevented any single blood test from meeting the rigorous requirements for a population screening programme. Private companies that offer multi-cancer screening blood tests — including some that claim to detect pancreatic cancer signals — should be approached with care, and any such testing should be discussed with a GP before proceeding, to understand both what the test can and cannot tell you and how results would be acted upon.
For people at high risk of pancreatic cancer — due to a relevant inherited gene mutation (BRCA1, BRCA2, PALB2, CDKN2A), Lynch syndrome with a first-degree relative with pancreatic cancer, or two or more first-degree relatives with the disease — Cancer Research UK notes that NICE recommends offering either an MRI scan or a magnetic resonance cholangiopancreatography (MRCP) as the preferred surveillance tool, not a blood test. If you have a family history that may place you in a higher-risk category, discussing this with your GP and asking about referral to a clinical genetics service is the most appropriate step. We can facilitate a prompt referral for imaging where clinically indicated.
Symptoms That Should Prompt Urgent Assessment
Given that pancreatic cancer rarely produces clear early symptoms, any persistent and unexplained combination of the following should prompt a GP assessment rather than a wait-and-see approach:
- Persistent upper abdominal pain or discomfort, often radiating to the back
- Jaundice — yellowing of the skin or whites of the eyes, which may be accompanied by dark urine and pale stools
- Unexplained weight loss of more than 5% of body weight over a short period
- New-onset diabetes without an obvious cause, particularly in adults over 50
- Changes in bowel habit — particularly pale, greasy stools that float and are difficult to flush
- Persistent nausea, loss of appetite, or a feeling of fullness
- Unexplained fatigue lasting more than a few weeks
- A newly palpable lump in the upper abdomen
Many of these symptoms are caused by conditions that are far more common and far less serious than pancreatic cancer. But because the consequences of delayed diagnosis in pancreatic cancer are so severe, they should always be investigated promptly rather than attributed to lifestyle or functional causes without proper assessment.
At The Private GP in Birmingham, a face-to-face GP consultation with same-day blood testing gives you direct access to a GMC-registered doctor who will assess your symptoms thoroughly, request the appropriate blood markers including liver function and CA19-9 where clinically indicated, and refer urgently for imaging if the findings or clinical picture warrant it. Same-day appointments are available. When it comes to symptoms that could indicate pancreatic cancer, acting promptly is always the right decision.
Frequently Asked Questions
- What blood tests are done for pancreatic cancer?
The primary blood tests used in the assessment of suspected pancreatic cancer are liver function tests (including bilirubin), CA19-9, CEA, a full blood count, and blood calcium. According to Pancreatic Cancer UK, NHS, and Lab Tests Online UK — in alignment with NICE guideline NG85 — these tests check general health, how well the liver and kidneys are functioning, and whether the tumour marker CA19-9 is elevated. None of these tests can diagnose pancreatic cancer independently; they are used alongside imaging and biopsy. A private blood test in Birmingham can provide same-day results on all of these markers with GP interpretation.
- Can a normal CA19-9 result rule out pancreatic cancer?
No. As Pancreatic Cancer UK and Lab Tests Online UK both clearly state, not all pancreatic cancers produce CA19-9 — and approximately 10% of people cannot produce this marker at all due to their blood group genetics. A normal CA19-9 result therefore does not exclude pancreatic cancer, particularly at an early stage. If you have persistent symptoms consistent with pancreatic cancer, a normal CA19-9 should not be used to dismiss further investigation. Clinical assessment and imaging remain essential.
- Is there a blood test that can detect pancreatic cancer early?
Not yet in routine clinical use. Research published in Clinical Cancer Research in 2026 from Queen Mary University of London identified a four-marker blood test that achieved 91.9% accuracy in distinguishing pancreatic cancer from non-cancer cases, and detected early-stage disease in 87.5% of cases — a significant advance over CA19-9 alone. However, the biomarkers require further prospective validation before the test enters clinical practice, and clinical implementation remains some years away. No blood test is currently recommended for general population pancreatic cancer screening in the UK.
- Does jaundice always mean pancreatic cancer?
No. Jaundice has many causes — including gallstones, hepatitis, cirrhosis, bile duct inflammation, and medication side effects — the majority of which have nothing to do with pancreatic cancer. However, painless jaundice in an adult over 40 should always be investigated promptly, as it can be a significant early sign of pancreatic cancer affecting the head of the pancreas. Liver function blood tests, followed by imaging, are the standard investigation pathway. If you develop jaundice, seek a same-day GP assessment rather than waiting for a routine appointment.
- Should I get a liver function blood test if I am worried about pancreatic cancer?
A liver function blood test is a sensible and clinically relevant starting point if you have symptoms that concern you — particularly jaundice, upper abdominal pain, or unexplained weight loss. Elevated bilirubin or liver enzymes can flag bile duct obstruction or liver involvement that warrants urgent imaging. However, a normal liver function test does not rule out pancreatic cancer. A comprehensive assessment combining blood tests, clinical history, and imaging provides the most complete picture. At The Private GP, our full health check-up service includes liver function assessment alongside a broad range of markers, with same-day results and GP review.